Study Shows Tylenol No Better Than Placebo & Hard on Your Liver


The study revealed how Tylenol is ineffective in the treatment of low back pain and provides minimal short term benefit for people with osteoarthritis. These results support the reconsideration of recommendations to use Tylenol for patients with low back pain and osteoarthritis of the hip or knee in clinical practice guidelines.

The New York Times reported on April 1, 2015 that Tylenol is no better than a placebo when given to patients seeking relief from spinal pain or disability. The Australian researchers, published online in The BMJ, analyzed 5, 366 patients. Acetaminophen (Tylenol) was given orally in doses between 3,000-4,000 milligrams per day.

What is even more alarming is the study confirms what the media and T&T blog posts have been saying for years: Tylenol is not safe and is particularly hard on your liver.  The first Tylenol bellwether trial is set for June 2015 in Pennsylvania.  The Tylenol multidistrict litigation alleges that the acetaminophen in various Tylenol products from a Johnson & Johnson Inc. is responsible for users’ severe liver damage.  U.S. District Judge Lawrence Stengel ordered jury selection to begin on June 22, 2015 for plaintiff Rana Terry’s suit accusing Johnson & Johnson and two subsidiaries of causing her sister’s death from acute liver failure.

Before taking large amounts of Tylenol, you should consult with your doctor on the best medication for your particular pain relief needs.

If you or a loved one has been injured from taking Tylenol, please contact our law firm. Follow our T&T Blog for further developments in the Tylenol Litigation.

Leave a Reply